Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy

Although immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment, the accuracy of predictive biomarkers for ICI outcomes, such as PD-L1, TMB (tumor mutation burden) or MMR (mismatch repair) deficiency, have not been satisfactory. ARID family members are essential for maintaining t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yan, Yan, Chun, Wang, Xiaofei, Xu, Zhijian, Lv, Jianjian, Xu, Xiaomei, Yu, Wenjun, Zhou, Mi, Yue, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896200/
https://www.ncbi.nlm.nih.gov/pubmed/35239432
http://dx.doi.org/10.1080/15384047.2021.2011643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896200/
https://www.ncbi.nlm.nih.gov/pubmed/35239432
http://dx.doi.org/10.1080/15384047.2021.2011643

Ejemplares similares